ImmuCell Co. (NASDAQ:ICCC - Get Free Report) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 5,700 shares, a decrease of 51.3% from the May 15th total of 11,700 shares. Based on an average daily volume of 25,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
Institutional Investors Weigh In On ImmuCell
Hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its position in shares of ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after buying an additional 14,982 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of ImmuCell during the 4th quarter valued at approximately $149,000. Geode Capital Management LLC lifted its position in shares of ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after buying an additional 7,878 shares in the last quarter. Dauntless Investment Group LLC purchased a new position in shares of ImmuCell during the 4th quarter valued at approximately $676,000. Finally, Mesirow Financial Investment Management Inc. lifted its position in shares of ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after buying an additional 12,178 shares in the last quarter. Hedge funds and other institutional investors own 13.47% of the company's stock.
ImmuCell Stock Performance
ImmuCell stock traded up $0.07 during mid-day trading on Friday, hitting $6.48. The company had a trading volume of 3,833 shares, compared to its average volume of 22,277. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. ImmuCell has a 12-month low of $3.34 and a 12-month high of $7.01. The company's fifty day moving average is $5.71 and its 200-day moving average is $5.26. The company has a market capitalization of $58.56 million, a price-to-earnings ratio of -12.96 and a beta of 0.30.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%. The business had revenue of $8.07 million for the quarter.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Recommended Stories
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
